Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
Open accessThe DOI matches its Crossref record; 195 of the 196 references it cites were found in a registry or an index.
Abstract
To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have antidepressive, anxiolytic, and antiaddictive properties. Thus, we conducted a systematic review of clinical trials published from 1990 until 2015, assessing these therapeutic properties. Electronic searches were performed using the PubMed, LILACS, and SciELO databases. Only clinical trials published in peer-reviewed journals were included. Of these, 151 studies were identified, of which six met the established criteria. Reviewed studies suggest beneficial effects for treatment-resistant depression, anxiety and depression associated with life-threatening diseases, and tobacco and alcohol dependence. All drugs were well tolerated. In conclusion, ayahuasca, psilocybin and LSD may be useful pharmacological tools for the treatment of drug dependence, and anxiety and mood disorders, especially in treatment-resistant patients. These drugs may also be useful pharmacological tools to understand psychiatric disorders and to develop new therapeutic agents. However, all studies reviewed had small sample sizes, and half of them were open-label, proof-of-concept studies. Randomized, double-blind, placebo-controlled studies with more patients are needed to replicate these preliminary findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse disorder, and alcohol use disorder, among others”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [171]
In the citing paper
“these medicines have demonstrated efficacy across a range of neuropsychiatric disorders including depression, PTSD, and addiction (156, 168–172)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [171]
In the citing paper
“Most of these studies however suffer from low methodological validity and are mostly open-label, yet they have yielded preliminary evidence for the capacity of psychedelic substances for treating addiction, depression, anxiety, and eating disorders (29–35).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [31]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Self-citationPsilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
Self-citationThe pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465
Plants of the Gods: Their Sacred, Healing and Hallucinogenic Powers
Hofmann, A., & Schultes, R. E. (1992) · Medical Entomology and Zoology · Cited by 463
Gasser, P., Kirchner, K., & Passie, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114555249 · Cited by 456
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Self-citationStrassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 411
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398
Enhanced repertoire of brain dynamical states during the psychedelic experience
Tagliazucchi, E., Carhart‐Harris, R., Leech, R., Nutt, D., & Chialvo, D. R. (2014) · Human Brain Mapping · doi:10.1002/hbm.22562 · Cited by 397
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 381
Psychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.
GROB, C. S., McKENNA, D. J., CALLAWAY, J. C., BRITO, G. S., NEVES, E. S., OBERLAENDER, G., SAIDE, O. L., LABIGALINI, E., TACLA, C., MIRANDA, C. T., et al. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199602000-00004 · Cited by 338
The Role of Monoamine Metabolism in Oxidative Glutamate Toxicity
Maher, P., & Davis, J. B. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-20-06394.1996 · Cited by 336
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Thomas, G., Lucas, P., Capler, N., Tupper, K., & Martin, G. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990003 · Cited by 330
Clinical Pharmacology of MAO Inhibitors: Safety and Future
Yamada, M. (2004) · NeuroToxicology · doi:10.1016/s0161-813x(03)00097-4 · Cited by 324
Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323
LSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312
ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE
Strassman, R. J. (1984) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198410000-00001 · Cited by 312
Vollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305
Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303
Self-citationPsychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 302
Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.005 · Cited by 298
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020009001 · Cited by 291
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266
Majić, T., Schmidt, T. T., & Gallinat, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568040 · Cited by 261
Psychedelic Drugs Reconsidered
Seelye, E. E. (1980) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1980.34.4.593 · Cited by 258
Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis
Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T. M., Stone, J. M., Evans, J., Sharp, D. J., Feilding, A., Wise, R. G., & Nutt, D. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs117 · Cited by 256
Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Krupitsky, E. M., & Grinenko, A. Y. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400185 · Cited by 246
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246
Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., & Barbanoj, M. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0358-7 · Cited by 241
Psychedelic Drugs Reconsidered
Grinspoon, L., & Bakalar, J. B. (1979) · Medical Entomology and Zoology · Cited by 239
Seeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion.
de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis, B. S., Crippa, J. A., Hallak, J. E. C., & Santos, A. C. (2012) · Human Brain Mapping · doi:10.1002/hbm.21381 · Cited by 239
Self-citationCarhart-Harris, R. L., Leech, R., Williams, T. M., Erritzoe, D., Abbasi, N., Bargiotas, T., Hobden, P., Sharp, D. J., Evans, J., Feilding, A., et al. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.103309 · Cited by 237
Moreno, J. L., Holloway, T., Albizu, L., Sealfon, S. C., & González-Maeso, J. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.01.046 · Cited by 234
van Amsterdam, J., Nutt, D., Phillips, L., & van den Brink, W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581980 · Cited by 229
Assessment of addiction severity among ritual users of ayahuasca.
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.024 · Cited by 227
Classic hallucinogens in the treatment of addictions
Bogenschutz, M. P., & Johnson, M. W. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.002 · Cited by 226
Visionary Vine: Hallucinogenic Healing in the Peruvian Amazon
de Ríos, M. D. (1972) · Medical Entomology and Zoology · Cited by 219
Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., & Riba, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.008 · Cited by 218
Self-citationHallucinogens, cross-cultural perspectives
de Ríos, M. D. (1984) · Cited by 215
Overview of Diagnosis and Drug Treatments of Anxiety Disorders
Nutt, D. J. (2005) · CNS Spectrums · doi:10.1017/s1092852900009901 · Cited by 211
Glennon, R. A., Dukat, M., Grella, B., Hong, S.-S., Costantino, L., Teitler, M., Smith, C., Egan, C., Davis, K., & Mattson, M. V. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00148-9 · Cited by 210
Harm potential of magic mushroom use: A review
Amsterdam, J. V., Opperhuizen, A., & Brink, W. V. D. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2011.01.006 · Cited by 208
Santos, R. G., Landeira-Fernandez, J., Strassman, R. J., Motta, V., & Cruz, A. P. M. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.04.012 · Cited by 205
Serotonin 5-HT2A Receptor Activation Blocks TNF-α Mediated Inflammation In Vivo
Nau, F., Yu, B., Martin, D., & Nichols, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075426 · Cited by 198
Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
Mckenna, D. J., Repke, D. B., Lo, L., & Peroutka, S. J. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90001-8 · Cited by 192
(2013) · PubMed · Cited by 192
Szabo, A., Kovacs, A., Frecska, E., & Rajnavolgyi, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106533 · Cited by 191
Glick, S. D., Kuehne, M. E., Raucci, J., Wilson, T. E., Larson, D., Keller, R. W., & Carlson, J. N. (1994) · Brain Research · doi:10.1016/0006-8993(94)90948-2 · Cited by 188
Buckholtz, N. S., & Boggan, W. O. (1977) · Biochemical Pharmacology · doi:10.1016/0006-2952(77)90007-7 · Cited by 184
Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence
Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V., Romanova, T. N., Slavina, T. Y., & Grinenko, A. Y. (2007) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2007.10399860 · Cited by 183
Hermle, L., Fünfgeld, M., Oepen, G., Botsch, H., Borchardt, D., Gouzoulis, E., Fehrenbach, R. A., & Spitzer, M. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90059-9 · Cited by 182
Frost, D., Meechoovet, B., Wang, T., Gately, S., Giorgetti, M., Shcherbakova, I., & Dunckley, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019264 · Cited by 178
The Psychopharmacology of Hallucinogens
Abraham, H., Aldridge, A. M., & Gogia, P. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00136-2 · Cited by 172
Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test
Farzin, D., & Mansouri, N. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.08.005 · Cited by 171
Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety
Nic Dhonnchadha, B. Á., Bourin, M., & Hascoët, M. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00311-x · Cited by 165
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2015-1701 · Cited by 160
Self-citationLoizaga-Velder, A., & Verres, R. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.873157 · Cited by 157
Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment
Brierley, D. I., & Davidson, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.001 · Cited by 156
Animal Models of Serotonergic Psychedelics
Hanks, J. B., & González-Maeso, J. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn300138m · Cited by 156
Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex
Pierce, P. A., & Peroutka, S. J. (1989) · Psychopharmacology · doi:10.1007/bf00443425 · Cited by 152
Moura, D. J., Richter, M. F., Boeira, J. M., Pegas Henriques, J. A., & Saffi, J. (2007) · Mutagenesis · doi:10.1093/mutage/gem016 · Cited by 152
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Stertz, L., Kapczinski, F., Pinto, J. P., Hallak, J. E., Zuardi, A. W., Crippa, J. A., et al. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.07.021 · Cited by 150
Self-citationDakwar, E., Levin, F., Foltin, R. W., Nunes, E. V., & Hart, C. L. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.009 · Cited by 143
Pharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141
Pharmahuasca: Human Pharmacology of Oral DMT Plus Harmine
Ott, J. (1999) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1999.10471741 · Cited by 140
dos Santos, R. G., Valle, M., Bouso, J. C., Nomdedéu, J. F., Rodríguez-Espinosa, J., McIlhenny, E. H., Barker, S. A., Barbanoj, M. J., & Riba, J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823607f6 · Cited by 136
mRNA Expression of Serotonin Receptors in Cells of the Immune Tissues of the Rat
Štefulj, J., Jernej, B., Čičin‐Šain, L., Rinner, I., & Schauenstein, K. (2000) · Brain Behavior and Immunity · doi:10.1006/brbi.1999.0579 · Cited by 131
(2008) · PubMed · Cited by 130
Pic‐Taylor, A., da Motta, L. G., de Morais, J. A., Melo, W., Santos, A. D. F. A., Campos, L. A., Mortari, M. R., von Zuben, M. V., & Caldas, E. D. (2015) · Behavioural Processes · doi:10.1016/j.beproc.2015.05.004 · Cited by 129
Current Considerations in the Treatment of Generalized Anxiety Disorder
Katzman, M. A. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00002 · Cited by 128
Winkelman, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107120011 · Cited by 126
Bogenschutz, M. P., & Pommy, J. M. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1376 · Cited by 125
The Internationalization of Ayahuasca
Macrae, E. (2012) · Journal of Contemporary Religion · doi:10.1080/13537903.2012.722324 · Cited by 124
Therapeutic infusions of ketamine: do the psychoactive effects matter?
Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.019 · Cited by 123
The psychedelic model of schizophrenia: the case of N,N- dimethyltryptamine
(1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.2.203 · Cited by 123
Report on psychoactive drug use among adolescents using ayahuasca within a religious context.
Doering-Silveira, E., Grob, C. S., de Rios, M. D., Lopez, E., Alonso, L. K., Tacla, C., & Da Silveira, D. X. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399794 · Cited by 122
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
Baumeister, D., Barnes, G., Giaroli, G., & Tracy, D. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314527985 · Cited by 121
Barbosa, P. C. R., Giglio, J. S., & Dalgalarrondo, P. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399801 · Cited by 120
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F. P., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A. S., & Quevedo, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.09.008 · Cited by 117
Self-citationLSD Revisited: A Ten-Year Follow-up of Medical LSD Use
McGlothlin, W. H. (1971) · Archives of General Psychiatry · doi:10.1001/archpsyc.1971.01750070037005 · Cited by 116
Ayahuasca in Adolescence: A Preliminary Psychiatric Assessment
Da Silveira, D. X., Grob, C. S., de Rios, M. D., Lopez, E., Alonso, L. K., Tacla, C., & Doering-Silveira, E. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399792 · Cited by 113
Health status of ayahuasca users
Barbosa, P. C. R., Mizumoto, S., Bogenschutz, M. P., & Strassman, R. J. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1383 · Cited by 112
Hallucinogenic Mushrooms in Mexico: An Overview
Guzmán, G. (2008) · Economic Botany · doi:10.1007/s12231-008-9033-8 · Cited by 111
Harmine and Imipramine Promote Antioxidant Activities in Prefrontal Cortex and Hippocampus
Réus, G. Z., Stringari, R. B., de Souza, B., Petronilho, F., Dal-Pizzol, F., Hallak, J. E., Zuardi, A. W., Crippa, J. A., & Quevedo, J. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.5.13109 · Cited by 110
Self-citationWhen the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor
Su, T.-P., Hayashi, T., & Vaupel, D. B. (2009) · Science Signaling · doi:10.1126/scisignal.261pe12 · Cited by 110
Frecska, E., Szabo, A., Winkelman, M. J., Luna, L. E., & McKenna, D. J. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1024-y · Cited by 109
Barbosa, P. C. R., Cazorla, I. M., Giglio, J. S., & Strassman, R. (2009) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2009.10400530 · Cited by 108
Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism
Schwarz, M. J., Houghton, P. J., Rose, S., Jenner, P. G., & Lees, A. J. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00129-1 · Cited by 106
The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells
Khor, B., Gagnon, J. D., Goel, G., Roche, M. I., Conway, K. L., Tran, K., Aldrich, L. N., Sundberg, T. B., Paterson, A. M., Mordecai, S., et al. (2015) · eLife · doi:10.7554/elife.05920 · Cited by 106
Serotonergic psychedelics temporarily modify information transfer in humans.
Alonso, J. F., Romero, S., Mañanas, M. À., & Riba, J. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv039 · Cited by 101
Self-citationThe Therapeutic Use of Ayahuasca
Labate, B., & Cavnar, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-40426-9 · Cited by 99
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F., Hallak, J. E., Zuardi, A. W., Crippa, J. A., & Quevedo, J. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0451-2 · Cited by 98
Self-citationEfficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962
Oram, M. (2014) · Journal of the History of Medicine and Allied Sciences · doi:10.1093/jhmas/jrs050 · Cited by 98
Riba, J., McIlhenny, E. H., Bouso, J. C., & Barker, S. A. (2015) · Drug Testing and Analysis · doi:10.1002/dta.1685 · Cited by 97
The internationalization of Ayahuasca
Jungaberle, H., & Labate, B. C. (2011) · Cited by 94
Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression
Li, Y., Sattler, R., Yang, E. J., Nunes, A., Ayukawa, Y., Akhtar, S., Ji, G., Zhang, P.-W., & Rothstein, J. D. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.016 · Cited by 93
‘Hitting Highs at Rock Bottom’: LSD Treatment for Alcoholism, 1950–1970
Dyck, E. (2006) · Social History of Medicine · doi:10.1093/shm/hkl039 · Cited by 91
Oliveira-Lima, A. J., Santos, R., Hollais, A. W., Gerardi-Junior, C. A., Baldaia, M. A., Wuo-Silva, R., Yokoyama, T. S., Costa, J. L., Malpezzi-Marinho, E. L. A., Ribeiro-Barbosa, P. C., et al. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.01.032 · Cited by 91
Self-citationNew World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
McKenna, D. J., & Riba, J. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_472 · Cited by 88
Hendricks, P. S., Clark, C. B., Johnson, M. W., Fontaine, K. R., & Cropsey, K. L. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113513851 · Cited by 88
Safety and Side Effects of Ayahuasca in Humans—An Overview Focusing on Developmental Toxicology
Guimarães dos Santos, R. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.763564 · Cited by 87
Persephone's Quest: Entheogens and the Origins of Religion
Wasson, R. G., Kramrisch, S., & Ruck, C. A. P. (1988) · Cited by 85
Morgan, C. J., Noronha, L. A., Muetzelfeldt, M., Feilding, A., & Curran, H. V. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113477744 · Cited by 83
[Ketamine--dreams and realities].
Arditti, J., Spadari, M., de Haro, L., Brun, A., Bourdon, J.-H., & Valli, M. (2002) · PubMed · Cited by 82
Relief of obsessive-compulsive symptoms by LSD and psilocin
Leonard, H. L., & RAPOPORT, J. L. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.9.1239b · Cited by 81
Sakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., Horiguchi, Y., & Taguchi, K. (2015) · Biological ^|^ Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00315 · Cited by 81
Hypotheses Regarding the Mechanisms of Ayahuasca in the Treatment of Addictions
Liester, M. B., & Prickett, J. I. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.704590 · Cited by 77
Lee, C. S., Han, E. S., Jang, Y. Y., Han, J. H., Ha, H. W., & Kim, D. E. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750521.x · Cited by 75
Buchborn, T., Schröder, H., Höllt, V., & Grecksch, G. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114531666 · Cited by 72
Effects of Psilocybe argentipes on Marble-Burying Behavior in Mice
MATSUSHIMA, Y., SHIROTA, O., KIKURA-HANAJIRI, R., GODA, Y., & EGUCHI, F. (2009) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.90095 · Cited by 71
Carbonaro, T. M., Eshleman, A. J., Forster, M. J., Cheng, K., Rice, K. C., & Gatch, M. B. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3658-3 · Cited by 66
EXPERIMENTAL PHYSIOLOGICAL STUDIES WITH LYSERGIC ACID DIETHYLAMIDE (LSD-25)
FORRER, G. R. (1951) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1951.02320050038004 · Cited by 66
Modulation of voltage‐gated channel currents by harmaline and harmane
Splettstoesser, F., Bonnet, U., Wiemann, M., Bingmann, D., & Büsselberg, D. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706024 · Cited by 65
Hallucinogens, Serotonin and Obsessive-Compulsive Disorder
Delgado, P. L., & Moreno, F. A. (1998) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1998.10399711 · Cited by 64
Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice
Dhonnchadha, B. Á. N., Hascoët, M., Jolliet, P., & Bourin, M. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00179-7 · Cited by 57
Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies
Ross, S. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.04.002 · Cited by 55
Psilocybin and Obsessive Compulsive Disorder
Wilcox, J. A. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.963754 · Cited by 54
Ayahuasca and the Treatment of Drug Addiction
Bouso, J. C., & Riba, J. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_6 · Cited by 52
Castro-Neto, E. F. D., Cunha, R. H. D., Silveira, D. X. D., Yonamine, M., Gouveia, T. L. F., Cavalheiro, E. A., Amado, D., & Naffah-Mazzacoratti, M. D. G. (2013) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v4.i4.141 · Cited by 52
Effects of harmaline on anxiety-related behavior in mice
Hilber, P., & Chapillon, P. (2005) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.07.006 · Cited by 52
Serotonin, Psilocybin, and Body Dysmorphic Disorder: A Case Report
Hanes, K. R. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00011 · Cited by 52
Wu, C., Jiang, X.-L., Shen, H.-W., & Yu, A.-M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.011 · Cited by 50
Iurlo, M., Leone, M. G., Schilström, B., Linnér, L., Nomikos, G. G., Hertel, P., Silvestrini, B., & Svensson, T. (2001) · Psychopharmacology · doi:10.1007/s002130100879 · Cited by 49
Krupitsky, E. M., Grineko, A. Y., Berkaliev, T. N., Paley, A. I., Tetrov, U. N., Mushkov, K. A., & Borodikin, Y. S. (1992) · Alcoholism Treatment Quarterly · doi:10.1300/j020v09n01_09 · Cited by 49
Sun, P., Zhang, S., Li, Y., & Wang, L. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.09.023 · Cited by 48
Bogenschutz, M. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990002 · Cited by 47
Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell
Brierley, D. I., & Davidson, C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112463125 · Cited by 45
Kolp, E., Young, M. S., Florida Mental Health Institute of University of South Florida, Friedman, H., University of Florida, Krupitsky, E., St. Petersburg State Pavlov Medical University, Jansen, K., O’Connor, L.-A., & Argosy University (2007) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2007.26.1.1 · Cited by 45
Liester, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107120522 · Cited by 45
Aricioǧlu-Kartal, F., Kayır, H., & Uzbay, T. I. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00647-7 · Cited by 44
Moreno, J. L., Holloway, T., Rayannavar, V., Sealfon, S. C., & González-Maeso, J. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2012.12.053 · Cited by 44
Psychedelic medicine: new evidence for hallucinogenic substances as treatments
(2008) · Choice Reviews Online · doi:10.5860/choice.45-2642 · Cited by 44
Immunological Consequences of In Vitro Exposure to Lysergic Acid Diethylamide (LSD)
House, R. V., Thomas, P. T., & Bhargava, H. N. (1994) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923979409029898 · Cited by 43
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
McKenna, D. J., & Riba, J. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_368 · Cited by 42
Self-citationRéus, G. Z., Stringari, R. B., Gonçalves, C. L., Scaini, G., Carvalho-Silva, M., Jeremias, G. C., Jeremias, I. C., Ferreira, G. K., Streck, E. L., Hallak, J. E., et al. (2012) · Depression Research and Treatment · doi:10.1155/2012/987397 · Cited by 40
Self-citationPsychedelic and Entactogenic Drugs in the Treatment of Depression
Riedlinger, T. J., & Riedlinger, J. E. (1994) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1994.10472600 · Cited by 39
Kolp, E., Friedman, H. L., Young, M. S., & Krupitsky, E. (2006) · The Humanistic Psychologist · doi:10.1207/s15473333thp3404_7 · Cited by 38
Experience of Treatment with Ayahuasca for Drug Addiction in the Brazilian Amazon
Fernández, X., & Fábregas, J. M. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_10 · Cited by 37
The therapeutic potentials of Ayahuasca in the treatment of depression
Palhano-Fontes, F., Alchieri, J. C., Oliveira, J. P. M., Soares, B. L., Hallak, J. E. C., Galvao-Coelho, N., & de Araujo, D. B. (2014) · The Therapeutic Use of Ayahuasca · doi:10.1007/978-3-642-40426-9_2 · Cited by 36
Self-citationFernández, X., dos Santos, R. G., Cutchet, M., Fondevila, S., González, D., Alcázar, M. Á., Riba, J., Bouso, J. C., & María Fábregas, J. (2014) · The Therapeutic Use of Ayahuasca · doi:10.1007/978-3-642-40426-9_11 · Cited by 36
Hollister, L. E., & Sjoberg, B. M. (1964) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(64)80030-4 · Cited by 35
Therapist and Patient Perspectives on Ayahuasca-Assisted Treatment for Substance Dependence
Loizaga-Velder, A. K., & Pazzi, A. L. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_8 · Cited by 33
Buchborn, T., Schröder, H., Dieterich, D. C., Grecksch, G., & Höllt, V. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.12.014 · Cited by 33
Physical harm due to chronic substance use
van Amsterdam, J., Pennings, E. J. M., Brunt, T. M., & van den Brink, W. (2013) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2013.03.007 · Cited by 32
Smith, D. E., Raswyck, G. E., & Davidson, L. D. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.873684 · Cited by 31
Young, S. N. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120128 · Cited by 30
Biradar, S. M., Joshi, H., & Tarak, K. C. (2013) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2013.1687.1697 · Cited by 25
Effects of 5-HT2A Receptor Stimulation and Blocking on Immune Response
Давыдова, С. М., Чейдо, М. А., Gevorgyan, M. M., & Idova, G. V. (2010) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-010-1109-7 · Cited by 24
Effect of Santo Daime Membership on Substance Dependence
Labate, B. C., SANTOS, R. G. D., Strassman, R. J., Anderson, B. T., & Mizumoto, S. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_9 · Cited by 21
Owaisat, S., Raffa, R. B., & Rawls, S. M. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.07.052 · Cited by 20
Ayahuasca psychedelic tested for depression
Frood, A. (2015) · Nature · doi:10.1038/nature.2015.17252 · Cited by 20
A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment
Burdick, B. V., & Adinoff, B. (2013) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.811513 · Cited by 18
Immunological Effects of Ayahuasca in Humans
dos Santos, R. G. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.960113 · Cited by 18
CLINICAL AND LABORATORY OBSERVATIONS ON LSD-25
FELD, M., Goodman, J. R., & GUIDO, J. A. (1958) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-195802000-00006 · Cited by 17
The Effect of Globopentaosylceramide on a Depression Model, Mouse Forced Swimming
Masuda, Y., & Sugiyama, T. (2000) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.191.47 · Cited by 14
Abelaira, H. M., Réus, G. Z., Scaini, G., STRECK, E. L., Crippa, J. A. S., & Quevedo, J. (2013) · Acta Neuropsychiatrica · doi:10.1017/neu.2013.20 · Cited by 13
Self-citationHallucinogens and Obsessive-Compulsive Disorder
Perrine, D. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1123 · Cited by 13
Zghoul, T., & Blier, P. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003218 · Cited by 12
Santini, M. A., Balu, D. T., Puhl, M. D., Hill‐Smith, T. E., Berg, A., Lucki, I., Mikkelsen, J. D., & Coyle, J. T. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.11.022 · Cited by 10
Endocrine and metabolic effects of lysergic acid diethylamide on female rats
Sackler, A. M., Weltman, A. S., & Owens, H. (1966) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(66)90128-1 · Cited by 7
Immunotoxicology of Opioids, Inhalants, and Other Drugs of Abuse
House, R. V., Thomas, P. T., & Bhargava, H. N. (1997) · PsycEXTRA Dataset · doi:10.1037/e495572006-012 · Cited by 7
Psychotropic Drugs in the Year 2000. Use by Normal Humans.
(1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-5-850_3 · Cited by 5
Effects of Lysergic Acid Diethylamide on the Total Leukocytes and Eosinophils of the Female Rat
Sackler, A. M., Weltman, A. S., & Sparber, S. B. (1963) · Nature · doi:10.1038/1991194a0 · Cited by 5
Schultes, R. E., Ceballos, L. F., & Castillo, A. (1986) · PubMed · Cited by 5
Research works printed but not linked: 16
- Furst P., 1994, Alucinógenos y cultura
- Grob C., 1998, Heffter Rev Psychedelic Res, 1, 8
- Grof S., 2001, LSD psychotherapy
- Halpern J., 2008, Med Sci Monit, 14, SR15
- Harner M., 1976, Alucinógenos y chamanismo
- Hintzen A., 2010, The pharmacology of lysergic acid diethylamide: a critical review
- Hofmann A., 2005, LSD: my problem child
- House R., 1997, NIDA Res Monogr, 173, 175
- Labate B., 2009, Ayahuasca religions: a comprehensive bibliography and critical essays
- Lima L., 2006, Ärztez Naturheilverfahren, 47, 476
- Ott J., 1994, Ayahuasca analogues: pangaean entheogens
- Ott J., 2004, Pharmacotheon: drogas enteogénicas, sus fuentes vegetales y su historia
- Réus G., 2012, Depress Res Treat, 2012, 987397
- Schultes R., 1986, Am Indig, 46, 9
- Schultes R., 1998, Heffter Rev Psychedel Res, 1, 1
- Sos P., 2013, Neuro Endocrinol Lett, 34, 287
Cited by
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Metadata
- Authors
- dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C.
- Affiliations
- Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, Brazil
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, SP, Brazil National Institute for Translational Medicine (INCT-TM), CNPq, Brazil
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
- Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-03-18
- Volume
- 6
- Issue
- 3
- Pages
- 193-213
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC4910400
- OpenAlex
- W2325558246
- Cited by
- 306
- References
- 196
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 50 · 2023: 28 · 2022: 32 · 2021: 44 · 2020: 35 · 2019: 27 · 2018: 29 · 2017: 20 · 2016: 5
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- ayahuasca, psilocybin, lysergic acid diethylamide, antidepressant effects, anxiolytic effects, treatment-resistant depression, anxiety disorders, drug addiction, tobacco dependence, alcoholism, psychedelics, mood disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.